Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination (Q63101722)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

title

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Judit Svensson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Maxime Dhainaut

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Henry Marsh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Joshua D Brody

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

14

Miriam Merad

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Ranjan Upadhyay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Shafinaz Hussein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Yougen Zhan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Dana Ostrowski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Michael Yellin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Thomas U Marron

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Andres M Salazar

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Adeeb H Rahman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Brian D Brown

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

language of work or name

English

0 references

publication date

8 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

814-824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30962585%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/s41591-019-0410-x

2 May 2020

exact match

0 references

cites work

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Quiescent Tissue Stem Cells Evade Immune Surveillance.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Innate and adaptive immune cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Classical Flt3L-dependent dendritic cells control immunity to protein vaccine

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

In vivo manipulation of dendritic cells to induce therapeutic immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

High-mobility group box 1 and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Systematic review of case reports on the abscopal effect

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Abscopal regression in lymphoma: a mechanism in common with total body irradiation?

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Hyperkalemia complicating splenic irradiation of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

The abscopal effect and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Improved vectors and genome-wide libraries for CRISPR screening

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

The ability of natural tolerance to be applied to allogeneic tissue: determinants and limits

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021

Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FS41591-019-0410-X

7 January 2021